MAM
SWTX

Meeder Asset Management’s SpringWorks Therapeutics SWTX Stock Holding History

Meeder Asset Management’s Portfolio SWTX Stock Details SWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-1,255
Closed -$80K – 2206
2021
Q3 		$80K Buy
1,255
+63
+5% +$4.86K ﹤0.01% 959
2021
Q2 		$98K Sell
1,192
-520
-30% -$39.5K ﹤0.01% 912
2021
Q1 		$127K Buy
+1,712
New +$134K 0.01% 852
2020
Q4 		– Sell
-384
Closed -$17K – 2202
2020
Q3 		$17K Buy
+384
New +$16.4K ﹤0.01% 1219

Other funds holding SWTX

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Meeder Asset Management's SWTX Position: Q4 2021 in Review

Meeder Asset Management sold out of SpringWorks Therapeutics (SWTX) in Q4 2021, closing a stake of 1,255 shares — an estimated $80K sold.

Meeder Asset Management first reported a position in SWTX in Q3 2020 and held it in 4 quarters. The position peaked at $127K in Q1 2021. 144 funds tracked by Wall St. Rank hold SWTX as of Q4 2021.

  • Meeder Asset Management reported no remaining SpringWorks Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Meeder Asset Management sold 1,255 SpringWorks Therapeutics shares in Q4 2021, an estimated $80K.
  • Meeder Asset Management first reported a position in SpringWorks Therapeutics in Q3 2020 and held it in 4 quarters.
  • Meeder Asset Management's SpringWorks Therapeutics position peaked at $127K in Q1 2021.
  • 144 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q4 2021.

Based on Meeder Asset Management's 13F filing for Q4 2021, filed 11 Feb 2022.